#Bourse #Pharma Pipeline Vs. Expiring Patents: Eli Lilly's Future - Seeking Alpha http://t.co/RGoWC1JZdA cc @ghabault
June 21, 2013
Publicité
/http%3A%2F%2Fstatic.cdn-seekingalpha.com%2Fuploads%2F2013%2F6%2F19%2Fsaupload_f6bb3671126419d5a957c186961f8198.png)
Pipeline Vs. Expiring Patents: Eli Lilly's Future
Notwithstanding management promulgations to the contrary, investors remain circumspect about Eli Lilly's ( LLY) ability to successfully navigate hurdles to earnings and cash flow growth following the loss of market protection of top-selling drugs in the next twelve months, including its flagship antidepressant Cymbalta (December 2013).